FierceBiotech Apr 23, 2026 Despite data concerns, Roche’s oral SERD can still be largest product in company history: exec
FierceBiotech Apr 23, 2026 From debt to ‘acceptable’ prices: Roche CEO lists 3 reasons for sitting out Big Pharma M&A spree
FierceBiotech Apr 22, 2026 Roche unpacks death imbalance, secondary endpoints in phase 3 multiple sclerosis trials
FierceBiotech Apr 20, 2026 AACR: Former Genentech leader engineers startup with vision for ‘smart’ cancer drugs
FierceBiotech Apr 9, 2026 Roche takes 'leap of faith' with $20M bet on C4T’s antibody-targeted protein degraders
FierceBiotech Mar 20, 2026 Genentech antibody fails to boost muscle in rare diseases, raising questions for obesity trial
FierceBiotech Mar 10, 2026 Lilly pledges $500M to South Korea biopharma industry, following Roche’s lead
FierceBiotech Mar 9, 2026 Roche's oral SERD flunks phase 3 trial in 1st-line breast cancer, raising questions of mechanism's limits
FierceBiotech Mar 6, 2026 Setting a new bar? Zealand touts 'placebo-like tolerability' for Roche-partnered weight loss drug
FierceBiotech Mar 4, 2026 Roche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem'
FierceBiotech Jan 29, 2026 Roche diagnostics business nudges up 2% in '25 as China headwinds buffet Asia-Pacific sales
FierceBiotech Jan 9, 2026 Roche returns to MediLink with promise of $570M near-term payments for another ADC
FierceBiotech Dec 10, 2025 Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial
FierceBiotech Dec 4, 2025 Paradigm Health raises $78M to revamp clinical research process, inks deal with Roche’s Flatiron